The Conversation (0)
- NORTH AMERICA EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Veracyte Receives Draft LCD for Percepta Bronchial Genomic Classifier
Sep. 16, 2016 01:51AM PST
Genetics InvestingVeracyte, a company providing genomic solutions in molecular cytology, has announced that Palmetto GBA posted a draft local coverage determination (LCD) for their Percepta Bronchial Genomic Classifier. The move follows the posting by Noridian Health on September 8, 2016.
Veracyte (NASDAQ:VCYT), a company providing genomic solutions in molecular cytology, has announced that Palmetto GBA posted a draft local coverage determination (LCD) for the Percepta Bronchial Genomic Classifier. The move follows the posting by Noridian Health on September 8, 2016.
As quoted in the press release:
The Percepta classifier is a genomic test designed for use in lung cancer diagnosis. The test is supported by multiple published studies demonstrating its ability to make lung cancer screening and diagnosis more accurate and safe by reducing unnecessary surgeries on suspicious lung nodules found on computed tomography (CT) scans.
According to Veracyte’s CEO, Bonni Anderson:
“We are moving quickly toward securing draft Percepta LCDs from all four MolDx Program participants. We appreciate Palmetto GBA’s vision in creating and administering this program, which establishes transparency in the coverage assessment process, and thereby facilitates patient and physician access to important innovations in the genomic testing field.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.